Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Casopitant; Neurokinin-1 Receptor Antagonists

Criteria

Inclusion criteria:

• History of PONV (postoperative nausea and vomiting) and/or motion sickness.

• Have not smoked for the last 6 months.

• Having certain abdominal, breast, thyroid or shoulder surgery.

Exclusion criteria:

• Pregnant or breastfeeding.

• Have certain pre-existing medical conditions or take certain medications.